Lupride 4mg Injection contains Leuprolide, a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH). It acts as a potent GnRH agonist, initially stimulating and subsequently suppressing the pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased production of sex hormones such as testosterone and estrogen. This pharmacological profile makes Lupride 4mg Injection effective in the management of hormone-responsive conditions including prostate cancer, endometriosis, uterine fibroids, and precocious puberty. Administered via intramuscular injection, the 4mg dose provides sustained release, allowing for monthly dosing. The suppression of gonadal steroidogenesis results in a reversible hypogonadal state, which is therapeutically beneficial in controlling disease progression and symptomatology. Clinicians should monitor patients for potential side effects such as hot flashes, injection site reactions, and transient tumor flare phenomena during initial treatment. Lupride 4mg Injection is contraindicated in pregnancy and hypersensitivity to leuprolide or any component of the formulation. It is essential to evaluate patients thoroughly before initiation and to adjust treatment based on clinical response and tolerability. This medication should be administered under the supervision of a healthcare professional experienced in managing hormone-dependent conditions.